AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Cancer Stress

Study Background and Research Question

Understanding how tumor cells adapt to metabolic and oxidative stress is critical for advancing therapeutic strategies in cancer biology. Non-small cell lung cancer (NSCLC) frequently harbors mutations in STK11/LKB1 and KEAP1, leading to metabolic vulnerabilities and compensatory activation of antioxidant pathways. The reference study (AUTOPHAGY 2024) investigates the regulatory interplay between the STK11-AMPK and KEAP1-NFE2L2/NRF2 signaling axes under metabolic stress, with the aim of unraveling mechanisms that underpin tumor resilience and growth.

Key Innovation from the Reference Study

The central innovation reported is the discovery of a double-positive feedback loop between AMP-activated protein kinase (AMPK) and the autophagy receptor SQSTM1/p62. This loop amplifies the activation of both AMPK and the NFE2L2/NRF2 antioxidant program, synergistically enhancing cellular defense mechanisms under nutrient deprivation and oxidative challenge. Notably, the study delineates how this feedback provides a mechanistic explanation for the frequent co-occurrence of STK11 and KEAP1 mutations in tumor evolution, and highlights new avenues for targeting metabolic adaptation in cancer cells.

Methods and Experimental Design Insights

The research employed a combination of cell biology, biochemical, and molecular genetic approaches to dissect the feedback mechanisms. Key experimental models included NSCLC cell lines and mouse embryonic fibroblasts (MEFs), with controlled induction of metabolic stress through glucose deprivation and pharmacological inhibitors.

• Protein expression and phosphorylation were monitored using immunoblotting and immunoprecipitation techniques to assess AMPK, SQSTM1/p62, and NFE2L2/NRF2 pathway activation.
• Lysosomal and endosomal acidification status was manipulated using V-type H⁺-ATPase inhibitors, such as Concanamycin A and bafilomycin A1, to probe the role of proton gradients in signaling crosstalk.
• Genetic knockdown and site-directed mutagenesis were utilized to define the functional importance of SQSTM1 phosphorylation at S24 and S226.
• ROS levels, NADPH/NADP⁺ balance, and cell viability assays were performed to connect molecular events to functional cellular outcomes.

Core Findings and Why They Matter

Key findings from the study include:

• Metabolic stress increases SQSTM1/p62 expression and phosphorylation, which is essential for NFE2L2 and AMPK activation. This dual activation underpins enhanced antioxidant defense and survival under stress.
• Double-positive feedback loop: The expression and phosphorylation of SQSTM1 are both induced by AMPK activity. In turn, phosphorylated SQSTM1 accelerates autophagic degradation of KEAP1 (the repressor of NRF2), thereby promoting NFE2L2/NRF2 activation. Simultaneously, SQSTM1 facilitates the assembly of the AXIN-STK11-AMPK complex at lysosomal membranes, further boosting AMPK signaling.
• Lysosomal deacidification is a central trigger: Low glucose metabolism and AMPK-dependent proton reduction lead to lysosomal deacidification. This, in turn, promotes PPP2/PP2A-dependent dephosphorylation of TFEB and TFE3, increasing SQSTM1 expression.
• SQSTM1 phosphorylation at S24 and S226 is mediated by MAP3K7/TAK1, which is activated by ROS and pH-dependent Ca²⁺ secretion. These phosphorylation events are critical for the feedback loop and subsequent pathway activation.
• The metabolic stress responses, including feedback activation, are abrogated by lactic acid, implicating proton supply and pH homeostasis in the regulation of these circuits.

These findings illuminate how metabolic and oxidative stress are integrated at the molecular level in cancer cells, clarifying the adaptive significance of STK11 and KEAP1 mutations and pinpointing vulnerabilities that could be therapeutically targeted.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on the experimental manipulation of lysosomal acidification and metabolic adaptation in cancer models:

• "Concanamycin A: V-type H+-ATPase Inhibitor for Tumor Research" emphasizes Concanamycin A's utility for probing endosomal acidification and apoptosis, aligning with the reference study's use of V-ATPase inhibitors to model metabolic stress and dissect signaling feedback.
• "Disrupting Cellular Acidification: Concanamycin A and the..." discusses how selective V-type H⁺-ATPase inhibition enables researchers to dissect cancer cell invasion and metabolic adaptation, directly paralleling experimental strategies in the reference paper.
• "Concanamycin A: Benchmark V-type H+-ATPase Inhibitor in Cancer Research" provides workflow guidance for apoptosis induction in tumor cells and supports the mechanistic framework observed in the reference study.

Collectively, these resources reinforce the critical role of selective V-ATPase inhibitors such as Concanamycin A in dissecting the interplay between metabolic stress, intracellular acidification, and cell fate decisions in cancer research.

Limitations and Transferability

Despite the comprehensive mechanistic insights, several limitations warrant consideration:

• Model specificity: The core feedback loop was demonstrated primarily in NSCLC models and MEFs. Its generalizability to other cancer types or primary tumor samples remains to be established.
• In vivo validation: Most evidence is derived from in vitro assays. Further studies are needed to confirm the physiological relevance and therapeutic potential of targeting the AMPK–SQSTM1 axis in animal models or clinical samples.
• Complexity of metabolic rewiring: Tumor microenvironmental factors, such as lactic acid levels and hypoxia, can modulate proton dynamics and may confound the feedback mechanisms in vivo.

Nonetheless, the feedback loop provides a robust conceptual framework for future studies targeting metabolic adaptation and redox homeostasis in cancer.

Protocol Parameters

• Concanamycin A treatment: 20 nM for 60 minutes is a commonly used protocol in cancer cell lines (e.g., HCT-116, DLD-1, HeLa, and prostate cancer lines LNCaP and C4-2B) to achieve effective V-type H⁺-ATPase inhibition and model endosomal acidification disruption, as reported in the product information and internal resource.
• Stock preparation: Concanamycin A is supplied as a 1 mg/mL solution in acetonitrile. For higher concentration stock solutions, warming at 37°C or using an ultrasonic bath is recommended. Stocks should be stored at -20°C and are not suited for long-term storage in solution form.
• Experimental note: Inhibition of endosomal acidification using Concanamycin A or bafilomycin A1 can be integrated into protocols to probe the impact of lysosomal pH on AMPK–SQSTM1–NFE2L2 pathway activation.

Research Support Resources

For researchers aiming to investigate the role of endosomal acidification and V-ATPase-mediated signaling in cancer adaptation, Concanamycin A (SKU A8633) offers a well-characterized, nanomolar-range V-type H⁺-ATPase inhibitor suitable for workflow integration in apoptosis and metabolic stress assays. The use of Concanamycin A facilitates robust modeling of the molecular mechanisms highlighted in the reference study, and its established protocols are supported by multiple cancer biology research articles. For further protocol optimization and troubleshooting, internal guides such as "Concanamycin A: Precision V-type H+-ATPase Inhibitor Workflows" are available. Researchers are encouraged to adapt dosing and handling based on cell type and experimental endpoints.